Intervacc AB and Dechra Pharmaceuticals PLC enter into an Agreement to Commercialize Strangvac in Europe
Stockholm, April 12, 2021 - Intervacc AB (“Intervacc”) announced today that they have entered into an exclusive distribution agreement with Dechra Pharmaceuticals PLC, (“Dechra”) to commercialize Intervacc’s leading vaccine candidate Strangvac in Europe, excluding the Nordic and Baltic countries where Intervacc will market and sell Strangvac directly. Strangvac is in late-stage regulatory review with the European Medicines Agency and is an innovative vaccine against equine strangles, a highly contagious infectious disease that affects horses globally.
The distribution agreement is based on Dechra purchasing finished products from Intervacc at an agreed transfer price plus additional future payments to Intervacc linked to pre-defined sales milestones. The agreement will run for a period of five years and Intervacc will remain the Market Authorization holder for Strangvac in Europe.
“We are excited to be entering into this partnership with Dechra to expand Strangvac’s market reach in Europe, where there is a significant medical need to prevent this highly contagious, debilitating disease. We selected Dechra as our exclusive partner as they are a high growth, global specialist veterinary business with a particular strength in the equine market. We look forward to working in close collaboration with Dechra to bring the innovative approach of Strangvac, which has shown great promise in clinical trials, to the European equine community as rapidly as possible.” said Andreas Andersson, CEO of Intervacc AB.
Ian Page, Chief Executive Officer of Dechra commented: “We are delighted to enter this collaboration with Intervacc. The addition of Strangvac will further strengthen our established European equine range by providing veterinarians with a novel product helping to prevent strangles in horses.”
Strangvac is a modern vaccine against strangles, a highly contagious and serious infection in horses caused by the bacterium Streptococcus equi. Strangvac, which consists of soluble recombinant proteins, is injected intramuscularly and is totally devoid of any living infectious agent. This results in a vaccine with an excellent safety profile. Strangvac is the first of what Intervacc expects to be a series of unique vaccine products for the animal health industry.
Intervacc is currently working with the European Medical Agency seeking approval for Strangvac in Europe and is forecasting approval in the second quarter of 2021.
For more information please contact:
Andreas Andersson, CEO
Phone: +46-8-120 10 601, cell +46-73-335 99 70
This information is information that Intervacc AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on April 12, 2021.
Intervacc AB is a Swedish company within animal health developing safe, effective vaccines for animals. The Company's vaccine candidates are based on several years of research at Karolinska Institutet and Swedish University of Agricultural Research where the foundation was laid for the Company´s research and development work. The Intervacc share has been listed on the Nasdaq First North Growth Market since April 2017 with Eminova Fondkommission AB, firstname.lastname@example.org, +46 (0)8–684 211 10 as Certified Adviser.
Dechra is a global specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.
For more information, please visit: www.dechra.com.
Contact information for Certified Adviser
Eminova Fondkommission AB
E-mail: email@example.com, Phone: +46 (0)8 – 684 211 10